Nonneutralizing Antibodies Induced by the HIV-1 gp41 NHR Domain Gain Neutralizing Activity in the Presence of the HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic Vaccine Strategy

ABSTRACT A key barrier against developing preventive and therapeutic human immunodeficiency virus (HIV) vaccines is the inability of viral envelope glycoproteins to elicit broad and potent neutralizing antibodies. However, in the presence of fusion inhibitor enfuvirtide, we show that the nonneutralizing antibodies induced by the HIV type 1 (HIV-1) gp41 N-terminal heptad repeat (NHR) domain (N63) exhibit potent and broad neutralizing activity against laboratory-adapted HIV-1 strains, including the drug-resistant variants, and primary HIV-1 isolates with different subtypes, suggesting the potential of developing gp41-targeted HIV therapeutic vaccines.

[1]  Lu Lu,et al.  Synergistic Effect Resulting From Combinations of a Bifunctional HIV-1 Antagonist With Antiretroviral Drugs , 2014, Journal of acquired immune deficiency syndromes.

[2]  Q. Wang,et al.  An engineered HIV-1 gp41 trimeric coiled coil with increased stability and anti-HIV-1 activity: implication for developing anti-HIV microbicides. , 2013, The Journal of antimicrobial chemotherapy.

[3]  Hong Lu,et al.  A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains , 2012, Retrovirology.

[4]  W. Koff.  HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem. , 2012, Vaccine.

[5]  Xue-qing Xu,et al.  A recombinant mimetics of the HIV-1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated mice. , 2010, Biochemical and biophysical research communications.

[6]  D. Montefiori,et al.  Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates , 2010, Proceedings of the National Academy of Sciences.

[7]  Hong Lu,et al.  Combinations of the First and Next Generations of Human Immunodeficiency Virus (HIV) Fusion Inhibitors Exhibit a Highly Potent Synergistic Effect against Enfuvirtide- Sensitive and -Resistant HIV Type 1 Strains , 2009, Journal of Virology.

[8]  Yan Guo,et al.  Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model , 2006, Vaccine.

[9]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[10]  A. Debnath,et al.  Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors , 2004, The Lancet.

[11]  S. Zolla-Pazner,et al.  Dissection of Human Immunodeficiency Virus Type 1 Entry with Neutralizing Antibodies to gp41 Fusion Intermediates , 2002, Journal of Virology.

[12]  P. Wingfield,et al.  Peptides Corresponding to the Heptad Repeat Motifs in the Transmembrane Protein (gp41) of Human Immunodeficiency Virus Type 1 Elicit Antibodies to Receptor-Activated Conformations of the Envelope Glycoprotein , 2001, Journal of Virology.

[13]  John P. Moore,et al.  Genetic Subtypes, Humoral Immunity, and Human Immunodeficiency Virus Type 1 Vaccine Development , 2001, Journal of Virology.

[14]  P. S. Kim,et al.  HIV Entry and Its Inhibition , 1998, Cell.

[15]  R. Lamb,et al.  A glycine to alanine substitution in the paramyxovirus SV5 fusion peptide increases the initial rate of fusion. , 1997, Virology.

[16]  Deborah Fass,et al.  Core Structure of gp41 from the HIV Envelope Glycoprotein , 1997, Cell.

[17]  Andrew H. Liu,et al.  CONVERGENT COMBINATION THERAPY CAN SELECT VIABLE MULTIDRUG-RESISTANT HIV-1 IN VITRO , 1995, Pediatrics.

[18]  Stephen C. Blacklow,et al.  A trimeric structural domain of the HIV-1 transmembrane glycoprotein , 1995, Nature Structural Biology.

[19]  T. Matthews,et al.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Shibo Jiang,et al.  HIV-1 inhibition by a peptide , 1993, Nature.

[21]  G. Salitra,et al.  Nested fullerene-like structures , 1993, Nature.